In 2025, Jiangsu led the nation in newly approved drugs and medical devices. Over the year, a total of 427 new drugs were approved for market launch in the province, including 17 innovative drugs, accounting for 22.37% of the national total, ranking first nationwide. Meanwhile, 566 Class III medical devices and 2,064 Class II medical devices received approval, both figures also topping the national rankings. In addition, 15 innovative medical devices were newly approved, accounting for 19.74% of the national total, propelling Jiangsu to the top nationwide in this category as well. In 2026, Jiangsu will integrate full-chain drug safety regulation with AI, further promoting high-level drug safety and high-quality development of the pharmaceutical industry.

In 2025, Jiangsu’s drug regulatory reform entered a new stage. China’s State Council has approved a plan to accelerate the opening-up and innovation of the entire biopharmaceutical industrial chain in the Jiangsu Pilot Free Trade Zone (FTZ). A total of 83 measures to advance in-depth reform of drug and medical device regulation were proposed and issued by the provincial government, with corresponding supporting policies introduced by drug regulatory authorities at both provincial and municipal levels, forming a comprehensive policy system to serve development.

Jiangsu took the lead nationwide in launching pilot reforms such as segmented production of biological products and streamlined supplementary drug applications, spearheaded the completion of the National Medical Products Administration’s “intelligent review and approval” project, and established a province-city coordinated, full-process service mechanism.

Over the past five years, Jiangsu has remained first nationwide in the number of approved drugs, innovative drugs and Class III medical devices, with revenue from the biopharmaceutical clusters exceeding 450 billion yuan. In 2026, Jiangsu’s drug regulation authorities will continue to undertake national-level reform pilots, further deepen reforms of the review and approval system, provide targeted services for local innovation projects, support the opening-up of pharmaceutical industry, improve the drug safety regulatory framework, and accelerate the modernization of drug governance.